TY - JOUR T1 - Mapping Psilocybin-Assisted Therapies: A Scoping Review JF - medRxiv DO - 10.1101/2019.12.04.19013896 SP - 2019.12.04.19013896 AU - Ron Joseph Shore AU - Paul Ioudovski AU - Sandra McKeown AU - Eric Dumont AU - Craig Goldie Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/12/17/2019.12.04.19013896.abstract N2 - We conducted a scoping review on psilocybin-assisted therapy for addiction, depression, anxiety and post-traumatic stress disorder. Psilocybin is a naturally-occurring tryptophan derivative found in species of mushroom with psycho-active properties. From 2022 records identified by database searching, 40 publications were included in the qualitative synthesis from which we identified 9 clinical trials with a total of 169 participants. Trials used a peak-psychedelic model of therapy, emphasizing inward journey through the use of eyeshades, set musical scores and with medium to high doses of psilocybin. No serious adverse effects were reported; mild adverse effects included transient anxiety, nausea and post-treatment headaches. Overall, the 9 trials all demonstrated safety, tolerability and preliminary efficacy in the treatments of obsessive-compulsive disorder, substance use disorder, treatment-resistant unipolar depression, anxiety or depression in patients with life-threatening cancer and demoralization among long-term AIDS survivors.The literature was found to be early and exploratory, with several limitations: only 5 were randomized controlled trials, small and homogenous patient sample size, difficulties in blinding, and the confounding influence of psychological supports provided. Further research is indicated to establish effectiveness for these and other indications, with a more diverse range of patients, and with differing program and dosing modalities. Keywords: psilocybin, psychedelic, psychedelic-assisted therapy, scoping review, depression, anxiety, obsessive-compulsive disorder, end-of-life distress, substance use disorderCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupplemental Information posted with article. Corresponding author may be reached at email provided for further information. ER -